Onconova Therapeutics (ONTX) reported a loss of $1.96 per share in its second quarter. The company reported revenue of $2.25 million, up 1775% on a year-over-year basis. Revenue beat consensus forecast by $0.85 million.

CASI Pharmaceuticals (CASI) reported a loss of $0.08 per share, missing consensus forecast by 4 cents. The company ended the quarter with $18.5 million in cash and cash equivalents on its balance sheet.

Vascular Biogenics (VBLT) reported a loss of $0.14 per share in its second quarter, beating consensus forecast by 9 cents. The company ended the quarter with $32.9 million in cash and cash equivalents on its balance sheet.

Meru Labs (MSLI) reported a net loss of $5.1 million in its third quarter. The company reported revenue of $25.7 million, up 170.2% on a year-over-year basis. Revenue beat consensus forecast by $5.17 million.

Mirna Therapeutics (MIRN) reported net income of $5.64 million in its second quarter. The company ended the quarter with $72.6 million in cash, cash equivalents and marketable securities on its balance sheet.

Corbus Pharmaceuticals (CRBP) reported a loss of $0.11 per share in its second quarter. The company reported revenue of $0.39 million, up 225% on a year-over-year basis.